Helen Louise Collins, Chief Medical Officer: Enliven Therapeutics ELVN Sell · Filed 05/20

Trade details

Type: Insider sale
Amount: $137,366.75
Shares · price: 3,475 sh · $39.53 a share
Held after: 26,525 sh
Stock: Enliven Therapeutics ELVN
Person: Helen Louise CollinsChief Medical Officer
Trade date: 26/05/18
Filed: 26/05/20
Days to filing: 2 days

Sold 11.6% of holdings

Share of holding sold: 11.6%

Enliven Therapeutics trades, last 26 weeks

What else happened in Enliven Therapeutics around then

Filed or reported within 30 days of the trade day · 04/18~06/17

Helen Louise Collins's recent trades

Helen Louise CollinsChief Medical Officer
Planned sale10b5-1 planEnliven Therapeutics
Planned sale10b5-1 plan
Enliven Therapeutics
ELVN
$762.9K
15,000 sh
$762.9K
Filed 07/17
Traded 07/17
Helen Louise CollinsChief Medical Officer
Sell10b5-1 planEnliven Therapeutics
Sell10b5-1 plan
Enliven Therapeutics
ELVN
$114K
2,599 sh
$114K
Filed 06/22
Traded 06/17
Helen Louise CollinsChief Medical Officer
Sell10b5-1 planEnliven Therapeutics
Sell10b5-1 plan
Enliven Therapeutics
ELVN
$54.3K
1,268 sh
$54.3K
Filed 06/22
Traded 06/17
Helen Louise CollinsChief Medical Officer
Sell10b5-1 planEnliven Therapeutics
Sell10b5-1 plan
Enliven Therapeutics
ELVN
$50.7K
1,133 sh
$50.7K
Filed 06/22
Traded 06/17
Helen Louise CollinsChief Medical Officer
Sell10b5-1 planEnliven Therapeutics
Sell10b5-1 plan
Enliven Therapeutics
ELVN
$52.4K
1,302 sh
$52.4K
Filed 05/20
Traded 05/18

Helen Louise Collins, Chief Officer — sold $137.4K of Enliven Therapeutics ELVN · 11.6% of holdings · 10b5-1 plan | Whalegun